Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LENS-HCC: Lenvatinib Followed by Surgical Resection for Initially Unresectable Hepatocellular Carcinoma
jRCTs031190057Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Eisai Co., Ltd. Primary endpoint: Surgical resection rate. Started Aug 2019; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031190057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190057.